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Abstract
The vacuolar ATPases are ATP-dependent proton pumps whose functions include the acidification of intracellular 
compartments and the extrusion of protons through the cell cytoplasmic membrane. These pumps play a pivotal role 
in the regulation of cell pH in normal cells and, to a much greater extent, in tumor cells. In fact, the glucose metabolism 
in hypoxic conditions by the neoplasms leads to an intercellular pH drift towards acidity. The acid microenvironment is 
modulated through the over-expression of H+ transporters that are also involved in tumor progression, invasiveness, 
distant spread and chemoresistance. Several strategies to block/downmodulate the efficiency of these transporters are 
currently being investigated. Among them, proton pump inhibitors have shown to successfully block the H+ 
transporters in vitro and in vivo, leading to apoptotic death. Furthermore, their action seems to synergize with 
conventional chemotherapy protocols, leading to chemosensitization and reversal of chemoresistance. Aim of this 
article is to critically revise the current knowledge of this cellular machinery and to summarize the therapeutic 
strategies developed to counter this mechanism.
Review
Tumor cells rely on H+ exchangers to relieve themselves
from the dangerous protons byproduct of cancer metabo-
lism that could trigger a cascade of lytic enzymes that
ultimately would lead to self-digestion. Among these the
most investigated are the vacuolar H+-ATPases (V-
ATPases). V-ATPases are ATP dependent H+ transporters
that utilize the energy freed by the hydrolysis of ATP with
the active transport of protons from the cytoplasm to the
lumen of intracellular compartments or, if located within
the cytoplasmic membrane, the extracellular compart-
ment [1-4]. Structurally speaking, the V-ATPases are
composed of a peripheral domain (V1) that carries out
ATP hydrolysis and an integral domain (V0) responsible
for exchanging protons. The peripheral domain is made
up of eight subunits (A-H) while the integral domain con-
tains six subunits (a, c, c', c", d and e). V-ATPases work
through a rotary mechanism in which ATP hydrolysis
within V1  promotes the rotation of a central rotary
domain, relative to the remainder of the complex, while
the rotation of a proteolipid ring belonging to V0 domain
moves protons through the membrane [5-7]. Two impor-
tant physiological mechanisms of regulating V-ATPase
activity in vivo are reversible dissociation of the V1 and V0
domains and changes in coupling efficiency of proton
transport and ATP hydrolysis [8-15]. Malignant tumor
cells overexpress lysosomal proteins on the cell surface,
with deranged lysosomal activities, including acidifica-
tion of internal vesicles, possibly involving altered V-
ATPase function [16,17]. The acidic tumor environment
is a consequence of anaerobic glucose metabolism with
secondary production of lactates byproducts through the
upregulation of hypoxia-inducible factor 1α [18] or can
be due to inadequate tumor perfusion, hypoxia secondary
to disordered tumor growth or enhanced transmembrane
pH regulation[19]. These pumps, coupled with other ion
exchangers, play a key role in the establishment and
maintenance of malignant tumor environment and pro-
mote the selection of more aggressive cell phenotypes
able to survive in this highly selective ambient.
Role of V-ATPases in tumor spread
V-ATPases play a critical role in the maintenance of an
appropriate relatively neutral intracellular pH, an acidic
luminal pH, and an acidic extracellular pH by actively
pumping protons either through ion exchange mecha-
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nisms or by segregating H+ within cytoplasmic organelles
that are subsequently expelled [20]. It is hypothesized
that the low extracellular pH of tumors might trigger pro-
teases, leading to the dissolution of extracellular matrix.
This phenomenon, as is well known, significantly con-
tributes to tumor invasion and dissemination [21,22]. In
fact, tumor invasion depends on tumor acidifying ability
that ultimately leads to secretion and activation of several
classes of proteases [23,24]. It is indeed known that low
extracellular pH can trigger several proteases such as
MMP-2, MMP-9, cathepsin B, and cathepsin L and result
in acidity-induced up-regulation of the proangiogenic
factors VEGF-A and IL-8 [25,26]. As a consequence, the
neutralization of these mechanisms has been actively
pursued by many investigators who have been only par-
tially successful, since so far it has been possible to block
one or more MMPases but not all them simultaneously
[27]. A recent publication points out that by inhibiting of
V-ATPases through RNA interference, it was possible to
prevent cancer metastases in a murine model [28]. This
approach offers a new strategy to cope with the process of
tumor spread (that is mediated by a continuous process
of extracellular matrix degradation and tumor angiogene-
sis) by raising the extracellular tumor pH, thus arresting
the activation of matrix degradating proteases. Finally,
besides being a potential target of anticancer drugs, it is
conceivable that V-ATPases might become a predictive
factor of tumor behaviour and final outcome through the
immunohistochemical evaluation of their expression and
cellular distribution in tumor biopsies [29-31].
Role of V-ATPases in chemoresistance
The acidic microenvironment caused by changes in the
pH gradient between the intracellular and the extracellu-
lar compartments as well as the pH gradient between the
cytoplasm and the intracellular organelles can be signifi-
cantly involved in the mechanism of drug resistance
[32,33]. There are several mechanisms involved in this
phenomenon, including decreased uptake or neutraliza-
tion of weakly basic drugs by the acidic tumor microenvi-
ronment or the sequestration of chemotherapy drugs
within lysosomal vesicles [32-36]. An accelerated turn-
over of acidic vesicles may represent an additional tumor
strategy of drug resistance based on counteracting cur-
rent transportation [37]. Several investigators developed
new approaches to better characterize tumor pH in ani-
mal models [38,39] mostly through imaging systems in
order to identify novel targets. As a result, new
approaches have been developed to modulate drug effi-
cacy within the low pH tumor milieu including the use of
RNA interference, bicarbonates or the induction of meta-
bolic alkalosis [40-43]. Finally, two recently published
articles describe the chemosensitizing action of proton
pump inhibitors (omeprazole) in a murine model of
orthotopic cutaneous melanoma, a well known chemo-
refractory neoplasm, opening a novel field of investiga-
tion [44,45].
Pump inhibitors as antitumor drugs
The various functions played by V-ATPases in tumors,
including proliferation, tumorigenesis, drug resistance
and tumor progression, make them potential targets for
preclinical investigators and clinicians. The evidence that
the expression of such proteins within tumor cells is
increased in chemoresistant phenotypes and the fact that
this expression could be induced by anticancer drugs,
prompted oncologists to pursue the pharmaceutical neu-
tralization of this tumor function [46-48]. Molecular and
pharmacological therapy of these biological targets is
technically extremely difficult and may carry a significant
degree of toxicity. On the other hand, proton pump
inhibitors are normally adopted in the treatment of gas-
tritis, Zollinger-Ellison syndrome and, limitedly to veteri-
nary oncology, gastric hyperacidity secondary to mast cell
tumors in dogs and cats [49]. These drugs have been
shown to be highly effective at inhibiting V-ATPases in
vitro and well tolerated and extremely efficacious in
murine models, resulting in increased chemotherapy effi-
cacy and improved tumor control [44,45,50]. Moreover,
the same schedule has been able to revert chemoresis-
tance to 5 fluorouracil, cisplatin and doxorubicin result-
ing in a caspase-independent cell death. Table 1
summarizes the different efflux pumps identified so far
within tumor cells and their role in the maintenance of
acid-base homeostasis and provides a short list of refer-
ences for each pump [21,35,51-59].
Conclusions
As a rule of thumb it is reasonable to speculate that pro-
ton pump inhibitors, being pro-drugs needing acidity to
be transformed in the active drug [59], might be more
active in the most acidic tumors. Some reports have
shown that metastatic tumors are more acidic then pri-
mary tumors, but also that solid tumors, either carci-
noma or melanomas or sarcomas, are more acidic than
systemic tumors (i.e. leukemia). It appears therefore con-
ceivable that proton pump inhibitors might be more
active against very malignant, often entirely unresponsive
to current therapy, tumors. In support to this hypothesis
it has also been shown that metastatic melanoma cells
may be grown in acidic condition while cells deriving
from primary tumors die when cultured in the same con-
dition, needing longer periods of adaptation to select
acid-resistant cells [60]. In fact, acidic condition increases
susceptibility of metastatic melanoma cells to proton
pump inhibitors [45]. Results of ongoing and future clini-
cal trials hopefully will provide the proof of concept that
inhibition of the proton pump may represent a newSpugnini et al. Journal of Experimental & Clinical Cancer Research 2010, 29:44
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approach in the war against cancer, by both improving
chemotherapy and inducing tumor self-digestion.
In conclusion, proton pump inhibitors might become a
crucial addition to the pharmaceutical "armoury" of
oncologists in consideration of their low cost, minimal
toxicity and high efficacy. Further preclinical and clinical
trials are ongoing to provide the clinical proof of concept
for the use of proton pump inhibitors in the treatment of
malignant cancers.
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